用 Targefrin 靶向胰腺癌转移-猫眼课题宝

用 Targefrin 靶向胰腺癌转移

批准号：

10763331

负责人：

Carlo Baggio

金额：

$40.0万

依托单位：

ARMIDA LABS, INC.

依托单位国家：

美国

项目类别：

财政年份：

2023

资助国家：

美国

项目状态：

已结题

起止时间：

2023-09-14 至 2024-08-31

来源：

https://reporter.nih.gov/project-details/10763331

关键词：

Abraxane Adult Affinity Albumins Azoles Binding Biopsy Breast Cell Line Clinical Clinical Research Clinical Trials Cytotoxic agent Detection Development Dose Drug Targeting End Point Assay EphA2 Receptor Esters Evaluation FDA approved Formulation Future Invaded Investigational Therapies Letters Ligands Link Malignant Neoplasms Malignant neoplasm of pancreas Measurement Names Neoplasm Metastasis Normal tissue morphology Oncogenic Oncologist Organ Paclitaxel Pancreas Patient Selection Patients Penetration Pharmaceutical Preparations Phase Primary Neoplasm Prognosis Property Prostate Protocols documentation Receptor Cell Receptor Protein-Tyrosine Kinases Reporting Research Personnel Serum Side Signal Transduction Site Small Business Innovation Research Grant Solid Neoplasm Surface Surrogate Endpoint Testing Therapeutic Tissues Toxic effect Tumor Markers Xenograft Model anti-cancer cancer cell cell motility chemotherapeutic agent chemotherapy circulating cancer cell design diagnostic strategy efficacy study first-in-human gemcitabine imaging study in vivo in vivo Model in vivo imaging innovation neoplastic cell novel novel diagnostics novel therapeutic intervention overexpression pancreatic cancer cells pancreatic cancer model pancreatic neoplasm pharmacologic receptor receptor internalization standard of care targeted agent targeted treatment tumor

中文摘要

翻译

点击翻译按钮获取中文摘要

英文摘要

ABSTRACT We intend to devise a novel therapeutic strategy based on a specific cancer cell receptor named EphA2, which is abundant on the surface of metastatic pancreatic cancers. Over the past several years our studies focused on testing the anti-cancer potential of agents targeting the receptor in suppressing cell migration and invasion in cellular studies, as well as in inhibiting tumor metastases using in vivo models. Very recently we have derived the most effective agonistic agent reported to date that potently targets the EphA2 receptor and causes its degradation. In preliminary studies, the agent is remarkably effective in inhibiting pancreatic cancer cell migration. The agent also causes the internalization of the receptor; hence we intend to probe whether we can use this agent also to deliver chemotherapy selectively to pancreatic tumors.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文

海外基金

Targeting pancreatic cancer metastases with Targefrin

项目摘要

项目成果

相似基金

相关文献